BRIEF-Lundbeck And Otsuka Announce U.S. FDA's Approval Of SNDA For Rexulti® (Brexpiprazole) For The Treatment Of Dementia Due To Alzheimer's Disease

Reuters · 05/11/2023 03:40
BRIEF-Lundbeck And Otsuka Announce U.S. FDA's Approval Of SNDA For Rexulti® (Brexpiprazole) For The Treatment Of Dementia Due To Alzheimer's Disease

- H Lundbeck A/S HLUNb.CO:

  • LUNDBECK AND OTSUKA ANNOUNCE U.S. FOOD AND DRUG ADMINISTRATION (FDA) APPROVAL OF SNDA FOR REXULTI® (BREXPIPRAZOLE) FOR THE TREATMENT OF AGITATION ASSOCIATED WITH DEMENTIA DUE TO ALZHEIMER'S DISEASE

Source text for Eikon: ID:

Further company coverage: [HLUNb.CO]


((Reuters.Briefs@thomsonreuters.com;))